-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
-
Sector Analysis
Melanoma: Epidemiology Forecast to 2035
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, which is the most superficial layer of the skin (World Health Organization, 2017). Melanoma typically presents as a mole (nevus) on the skin, and is characterized by the growth’s asymmetry, irregular border, color variation, diameter greater than six millimeters, and evolution in appearance over a few weeks or months (Gadeliya Goodson and Grossman, 2009; Goodman and Snyder, 2012). This report focuses on melanoma...
-
Sector Analysis
The Drive Towards Healthcare Self-Sufficiency in Latin America
Following on from the COVID-19 pandemic, which exposed the region's dependence on imported health products, Latin American countries have been striving to become increasingly self-sufficient in providing for their own healthcare needs. The move towards greater self-sufficiency is being spearheaded by larger economies such as Brazil and Mexico but is also being mirrored on a smaller scale by others. In this Strategic Report, GlobalData explores some of the main initiatives that have been adopted in order to achieve this, both...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, June 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Track & Monitor
Merger and Acquisition Trends in Pharma - Q2 2026
This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
-
Sector Analysis
Three Possible Scenarios for MFN Implementation in the US: What Can Pharma Expect and What Are the Possible Strategies to Protect Revenue
Just over a year ago, US President Donald Trump signaled his intent to introduce international reference pricing (IRP) for medicines in the US through the May 2025 Most Favored Nation (MFN) executive order. Based on GlobalData's extensive repository of IRP knowledge and daily tracking of pricing and reimbursement developments around the world, in this strategic report GlobalData explores alternative scenarios for MFN implementation and what these mean for the pharmaceutical industry, with a particular focus on how to protect pharma...
-
Sector Analysis
Emerging Market Outsourcing Report, Q2 2026
Report Value Proposition – Why Does Pharma Outsourcing Matter? Pharmaceutical outsourcing continues to play a critical role in helping drug manufacturers improve efficiency, reduce costs, and accelerate product development. As emerging markets expand their manufacturing capabilities, contract manufacturing organizations (CMOs) are becoming increasingly important partners across active pharmaceutical ingredient (API) production, biologics, drug formulation, packaging, and commercial manufacturing. GlobalData's Emerging Pharma Market Outsourcing report provides a comprehensive analysis of pharmaceutical manufacturing trends across emerging markets, with a particular focus on...
-
Sector Analysis
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape
Why Does the FSGS Therapeutics Market Matter? Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease characterized by scarring of the glomeruli and can lead to progressive kidney dysfunction. The treatment landscape is undergoing a significant shift as disease-specific therapies emerge alongside established supportive and off-label treatment approaches. GlobalData’s Focal Segmental Glomerulosclerosis (FSGS): Market View provides a data-driven assessment of the current and future competitive landscape, combining Pharma Intelligence Center data with in-house analyst expertise. In 2025, there were 37,049...
-
Consumer Insights
Industry Insights: How Dietary Supplements Have Evolved Beyond Traditional Health Management
This report highlights the shift in consumer preferences from traditional health supplements to modern formats designed to address specific health needs. As people become more health-conscious, they are increasingly seeking tailored, localized products that support longevity and overall vitality. Growing interest in these contemporary supplements is largely fueled by online marketing and easier access to health information through social media. The report explores consumer interest in nootropics, nutricosmetics, and cellular health supplements. As health and wellness become a higher priority...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.